Lung/Bronchial NETs

PRRT Trials

• Alpha PRRT with Pb-212 (all NET)

• Lu-177 DOTATATE + Cabozantanib (all NET)

• Lu-177 DOTATATE vs Everolimus in Lung NETs

Other Trials

• Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs

• CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy

• Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)